CCL2 and head and neck squamous cell carcinoma: Within this ex-vivo study, we confirm that compared to pembrolizumab and TP reduced MCP-1 concentrations through combined pembrolizumab + TP is an indicator for HNSCC patients with rather good outcome according to OS, DSS, and PFS.